Literature DB >> 19910932

Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study.

Francesco Fallo1, Anna Dalla Pozza, Matteo Tecchio, Francesco Tona, Nicoletta Sonino, Mario Ermani, Cristiana Catena, Chiara Bertello, Paolo Mulatero, Nicoletta Sabato, Bruno Fabris, Leonardo A Sechi.   

Abstract

BACKGROUND: An impairment of glucose metabolism, contributing to the increased cardiovascular risk, has been shown in primary aldosteronism (PA). Insulin resistance is associated with nonalcoholic fatty liver disease (NAFLD) and may play a role in its pathophysiology. The aim of this study was to investigate the association between NAFLD and PA, and to identify determinants of NAFLD in this condition.
METHODS: A total of 40 patients with PA, 40 sex-, age-, and body mass index matched patients with low-renin essential hypertension (LREH) and 40 normotensive subjects were studied. According to ultrasound detection of fatty liver, each group was subdivided in two subsets: with NAFLD and without NAFLD. Patients with diabetes, obesity, and hyperlipidemia were excluded.
RESULTS: Prevalence of NAFLD in PA was similar to that observed in LREH patients, and higher (P < 0.01) than in normotensive controls. Serum potassium was lower in PA than in LREH patients with NAFLD (P < 0.001), while it was similar in PA and LREH patients without NAFLD. At univariate analysis, plasma aldosterone, homeostasis model assessment (HOMA) index and hypokalemia were determinants of NAFLD in PA (P < 0.05), while HOMA index was associated with NAFLD in LREH (P < 0.05). At multivariable analysis, only hypokalemia remained associated with NAFLD in PA (P = 0.02).
CONCLUSIONS: The results of this pilot study suggest that, in the absence of major risk factors for liver disease, NAFLD is a frequent finding in PA. Patients with PA and hypokalemia are more insulin resistant and have higher prevalence of NAFLD than those with normokalemia, indicating greater risk for metabolic and liver disease in this subgroup.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910932     DOI: 10.1038/ajh.2009.206

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  15 in total

1.  Adrenal cell aldosterone production is stimulated by very-low-density lipoprotein (VLDL).

Authors:  Yewei Xing; William E Rainey; John W Apolzan; Omar L Francone; Ruth B S Harris; Wendy B Bollag
Journal:  Endocrinology       Date:  2011-12-20       Impact factor: 4.736

Review 2.  Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease.

Authors:  Guanghong Jia; Warren Lockette; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-01-13       Impact factor: 3.619

3.  RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.

Authors:  Suman Srinivasa; Kathleen V Fitch; Kimberly Wong; Martin Torriani; Caitlin Mayhew; Takara Stanley; Janet Lo; Gail K Adler; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2015-06-18       Impact factor: 5.958

4.  Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals.

Authors:  A Mantovani; G Zoppini; G Targher; G Golia; E Bonora
Journal:  J Endocrinol Invest       Date:  2012-02       Impact factor: 4.256

Review 5.  Secondary diabetes mellitus due to primary aldosteronism.

Authors:  Melpomeni Moustaki; Stavroula A Paschou; Eleni C Vakali; Andromachi Vryonidou
Journal:  Endocrine       Date:  2022-08-24       Impact factor: 3.925

Review 6.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 7.  Effects of aldosterone on insulin sensitivity and secretion.

Authors:  James M Luther
Journal:  Steroids       Date:  2014-09-04       Impact factor: 2.668

Review 8.  The mineralocorticoid receptor-an emerging player in metabolic syndrome?

Authors:  Moe Thuzar; Michael Stowasser
Journal:  J Hum Hypertens       Date:  2021-02-01       Impact factor: 3.012

9.  Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population.

Authors:  Yi Chen; Xueyang Chen; Qiang Chen; Chaohui Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-22       Impact factor: 5.555

10.  Significant Association of Aldosterone and Liver Fat Among HIV-Infected Individuals With Metabolic Dysregulation.

Authors:  Suman Srinivasa; Kathleen V Fitch; Nabiha Quadri; Patrick Maehler; Timothy K O'Malley; Edgar L Martinez-Salazar; Tricia H Burdo; Meghan Feldpausch; Martin Torriani; Gail K Adler; Steven K Grinspoon
Journal:  J Endocr Soc       Date:  2018-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.